Proceedings · Session S-191 · filed November 16, 2026

Lab Technology & MethodsSession paper

Salk's Superb-seq Finds 36 Off-Target Sites in 43 CRISPR Edits

Salk's Superb-seq pairs Cas9 edit capture with single-cell transcriptomics, finding 36 off-target sites among 43 edits across 34,000 cells in Nature Methods.

By Rebecca Stone3 min read656 words

Summary

  • Superb-seq detected 43 edit sites from seven guide RNAs, of which 36 were off-target, in 10,000 human leukemia cells.
  • The method was validated on 34,000 cells from three cell lines and captured 5,761 edited cells at single-cell resolution.
  • The paper was published in Nature Methods by Salk Institute researchers led by Graham McVicker, PhD.
  • Superb-seq combines Cas9 editing, T7 transcription, and single-cell RNA sequencing to link edits to gene expression changes.
  • McVicker, Lorenzini, and Balderson have filed a patent for the method.
Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression
FigureSingle-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression — Vector8DIY / pixabay

Seven guide RNAs aimed at human leukemia cells produced 43 edit sites — and 36 of those sites were off-target, according to a new single-cell method developed at the Salk Institute. The tool, called Superb-seq, captured both the edits and their consequences for gene expression in 5,761 edited cells, and its developers report that the frequency of unwanted cuts surprised even them.

The method is described in a Nature Methods paper titled "Joint single-cell capture of Cas9 edits and transcriptomes reveals on- and off-target effects on gene expression." Graham McVicker, PhD, senior author and associate professor at Salk, said the work began with a practical gap in the CRISPR workflow.

"What really inspired Superb-seq was a frustration with the existing state of affairs," McVicker said. "We knew there were problems with CRISPR making unwanted edits, but also there was no good way to see what those edits were and how they affected the cell—what we wanted to see was invisible using current technologies."

How does the method work?

Superb-seq integrates three components in a single pipeline: Cas9 editing, T7 transcription (an in vitro step that amplifies edit sites for reading), and single-cell RNA sequencing. The combination lets researchers capture, cell by cell, both the exact edits Cas9 has made and the transcriptome — the full set of RNA molecules that indicates which genes are active — in that same cell.

That joint readout is the distinguishing feature. The team validated the approach on 34,000 cells drawn from three different cell lines. In the leukemia-cell experiment, 10,000 cells were edited using seven guide RNAs (the short RNA molecules that direct Cas9 to a genomic location). The 43 detected edit sites included the intended targets plus the 36 off-target cuts.

The scale of the off-target problem deserves attention from any lab using CRISPR routinely, McVicker argued. "There are some people that have worked on this off-target issue before that have an awareness of how bad it is, but for many people that pick up CRISPR to use in the lab, the extent of this problem will really come as a surprise," he said. "I knew off-targets were an issue, but they were far more frequent than I was expecting."

What does it change for R&D teams?

Superb-seq addresses two limitations that currently shape how CRISPR experiments are interpreted. First, existing edit-detection methods miss gene expression changes caused by genome edits; Superb-seq detects those changes. Second, it improves on Perturb-seq, a widely used approach that reads out gene expression and guide RNAs but cannot see the edits that actually resulted.

The method shows where unwanted edits sit in the genome and how those edits disrupt key genes that protect cells against unhealthy states — information that speaks directly to experiment reproducibility.

Michael Lorenzini, PhD, a first author and staff scientist in McVicker's lab, flagged a retrospective implication for published work: "Superb-seq could reveal the extent to which off-target edits color all those findings" in existing CRISPR-based studies of biology.

Where does it fit in drug development?

The developers position the tool at the candidate-profiling stage of genome therapy programs. "Our tool could be immensely helpful in establishing the safety of genome therapy candidates early on in development. Superb-seq could be used to profile candidates and learn what their off-target edits are, as well as their effects," Lorenzini said.

The team also sees a data-generation role: Superb-seq could produce paired edit-and-expression training sets for machine learning models of cellular function, where measured outcomes at single-cell resolution are scarcer than expression data alone.

McVicker, Lorenzini, and co-author Brad Balderson, PhD, have filed a patent on the method — a signal that commercialization, licensing terms, and instrument integration may follow as the technique moves beyond the three cell lines tested so far.

via nature.com (Original)

Filed under

  • crispr
  • superb-seq
  • single-cell-rna-sequencing
  • off-target-effects
  • genome-editing
Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Market editor covering regulation, policy and their impact on research and development at Hypothesis Wire.

274 articles

References

  1. Beyond Cas9: Gene Editing's Second Act Spans Pig Kidneys to Stem Cells
  2. David Liu advances disease-agnostic gene editing at ESGCT
  3. Takara Bio USA Pairs NGS Library Prep with SPT Labtech Firefly
  4. Anthropic's Claimed AI Biology 'Discovery' Draws Sharp Pushback
  5. CRISPR-Transposon Platform Maps Essential Phage Genes Genome-Wide

« Previous articleNext article »